ECSP22037660A - Agonistas del receptor npy2 - Google Patents

Agonistas del receptor npy2

Info

Publication number
ECSP22037660A
ECSP22037660A ECSENADI202237660A ECDI202237660A ECSP22037660A EC SP22037660 A ECSP22037660 A EC SP22037660A EC SENADI202237660 A ECSENADI202237660 A EC SENADI202237660A EC DI202237660 A ECDI202237660 A EC DI202237660A EC SP22037660 A ECSP22037660 A EC SP22037660A
Authority
EC
Ecuador
Prior art keywords
receptor agonists
analogs
npy2 receptor
relates
npy2
Prior art date
Application number
ECSENADI202237660A
Other languages
English (en)
Inventor
Soren Pedersen
Albert Brennauer
Charlotte Madsen
Peter Haebel
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22037660A publication Critical patent/ECSP22037660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a análogos de PYY que tienen alanina en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de semivida. Los análogos de la invención son solubles a alrededor de pH 6 y 7. La invención también se refiere a composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos.
ECSENADI202237660A 2019-11-11 2022-05-11 Agonistas del receptor npy2 ECSP22037660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (1)

Publication Number Publication Date
ECSP22037660A true ECSP22037660A (es) 2022-06-30

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202237660A ECSP22037660A (es) 2019-11-11 2022-05-11 Agonistas del receptor npy2

Country Status (20)

Country Link
US (3) US20210139548A1 (es)
EP (1) EP4058047A1 (es)
JP (2) JP7821393B2 (es)
KR (1) KR20220100925A (es)
CN (1) CN114641303A (es)
AR (1) AR120440A1 (es)
AU (1) AU2020384729A1 (es)
CA (1) CA3156452A1 (es)
CL (1) CL2022001227A1 (es)
CO (1) CO2022006046A2 (es)
CR (1) CR20220206A (es)
DO (1) DOP2022000097A (es)
EC (1) ECSP22037660A (es)
IL (1) IL292601A (es)
JO (1) JOP20220110A1 (es)
MX (1) MX2022005661A (es)
PE (1) PE20221168A1 (es)
PH (1) PH12022551101A1 (es)
TW (1) TWI864155B (es)
WO (1) WO2021094259A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CR20250247A (es) * 2022-12-21 2025-08-18 Boehringer Ingelheim Int Agonistas triples de los receptores de glp1/gip/npy2
WO2024225848A1 (ko) 2023-04-28 2024-10-31 주식회사 피노바이오 항체에 하나 이상의 약물-링커 접합체가 결합된 항체-약물 접합체 및 이의 제조방법

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512365A (ja) 2003-11-25 2007-05-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 選択的神経ペプチドｙ２受容体作動薬
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
MX2007006830A (es) 2004-12-13 2008-02-07 Amylin Pharmaceuticals Inc Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
RU2430108C2 (ru) 2005-12-07 2011-09-27 Ф.Хоффманн-Ля Рош Аг Агонисты рецептора нейропептида-2
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
KR20100098628A (ko) 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011058165A1 (en) 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
PH12012502472A1 (en) 2010-06-24 2013-03-25 Zealand Pharma As Glucagon analogues
WO2012168431A2 (en) 2011-06-10 2012-12-13 Novo Nordisk A/S Polypeptides
WO2013092703A2 (en) 2011-12-23 2013-06-27 Zealand Pharma A/S Glucagon analogues
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
ES2660788T3 (es) 2013-11-14 2018-03-26 Keybioscience Ag Miméticos de la calcitonina para el tratamiento de enfermedades y trastornos
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
US10583172B2 (en) * 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
MA43205A (fr) * 2015-06-12 2018-09-19 Novo Nordisk As Composés pyy sélectifs et leurs utilisations
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
JP2019517787A (ja) 2016-05-03 2019-06-27 ザ スクリプス リサーチ インスティテュート 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
CN108289005B (zh) 2017-01-09 2021-06-29 中兴通讯股份有限公司 信令发送、接收方法及装置
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
US10581312B2 (en) 2017-12-29 2020-03-03 Texas Instruments Incorporated Multilevel converter using node voltage track and control
JP2021512051A (ja) 2018-01-23 2021-05-13 ギラ セラピューティクス インコーポレイテッドＧｉｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドｙｙ薬学的調剤物、組成物、および方法
TWI847981B (zh) 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2

Also Published As

Publication number Publication date
JP7821393B2 (ja) 2026-02-27
DOP2022000097A (es) 2022-06-15
US12054525B2 (en) 2024-08-06
JOP20220110A1 (ar) 2023-01-30
TWI864155B (zh) 2024-12-01
US20250002544A1 (en) 2025-01-02
IL292601A (en) 2022-07-01
TW202134263A (zh) 2021-09-16
CL2022001227A1 (es) 2023-02-03
AU2020384729A1 (en) 2022-04-14
PE20221168A1 (es) 2022-07-25
JP2026026081A (ja) 2026-02-16
US20210139548A1 (en) 2021-05-13
KR20220100925A (ko) 2022-07-18
AR120440A1 (es) 2022-02-16
WO2021094259A1 (en) 2021-05-20
CO2022006046A2 (es) 2022-05-20
CN114641303A (zh) 2022-06-17
CA3156452A1 (en) 2021-05-20
EP4058047A1 (en) 2022-09-21
PH12022551101A1 (en) 2023-11-13
CR20220206A (es) 2022-06-16
JP2023500895A (ja) 2023-01-11
MX2022005661A (es) 2022-09-07
US20230340039A1 (en) 2023-10-26
US12559529B2 (en) 2026-02-24

Similar Documents

Publication Publication Date Title
CL2023000357A1 (es) Agonistas del receptor npy2 solubles
ECSP22037660A (es) Agonistas del receptor npy2
MX392572B (es) Compuestos del péptido yy (pyy) selectivos y sus usos.
MX2020006474A (es) Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
JOP20210089A1 (ar) نظائر بروتين تيروسين-تيروسين وطرق لاستخدامها
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CL2021003273A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
NZ743489A (en) Controlled-release cnp agonists with low npr-c binding
BR112022006297A2 (pt) Agonistas de receptor de npy2
EA202290107A1 (ru) Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
EA202192475A1 (ru) Способ получения стабильных пептидных составов
EA202191511A1 (ru) Составы на основе аналога пептида оксинтомодулина
AR113966A1 (es) LIGANDOS PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EphA2